With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

Manav Midha is an MD candidate at the Icahn School of Medicine at Mount Sinai and a researcher at the USC Schaeffer Center ...

An often cited example of the importance of including a wide sample of patients is research showing that certain drugs can be ...

The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in adults with alkaptonuria, Cycle ...

The 7-2 opinion comes as companies push back against a yearslong federal regulatory crackdown on electronic cigarettes. It's ...

Note that some links may require registration or subscription. Three people died and 16 have been hospitalized in a listeria ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The news comes amid concerning trends in U.S. alcohol consumption and associated health risks, including an alarming surge in alcohol-related hospitalizations and liver transplants in younger ...

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why these results matter for amyloidosis -- and how innovations across plasma ...

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).